- Date October 2020
- Therapeutic Area Idiopathic Pulmonary Fibrosis
- Study Type Phase II | Rescue
- Challenges COVID-19 Pandemic | High patient burden (1-year-long commitment)



Phase II clinical study for patients with IPF.
Responsum was brought in to boost enrollment in the US market quickly, as existing efforts had failed. The campaign has been slow in the US. 20+ randomized patients needed quickly.
Strategy and results:
Leveraging our 3.6K+ member pulmonary fibrosis community, we launched a targeted campaign centered on clinical trial education, streamlined phone screening, and a personalized email drip campaign designed to align with participants’ preferences and demographics.
52 patients were referred successfully, 13 screened, and 8 randomized. All from our IPF community.


“We got 300% grown result from being at a coworking space compared to working from home/coffee shops. We’re far more settled and happy in this company!”